Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 9,945

Document Document Title
WO/2012/043577A1
The problem addressed by the present invention is the provision of: a reversing agent that reverses the anticoagulant effects of an FXa inhibitor; and/or a reversal method using said reversing agent. [Solution] A reversing agent for an o...  
WO/2012/037466A3
Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and...  
WO/2012/035209A1
The present invention relates to compositions and methods of inhibiting, treating or preventing age related or other retinal diseases, neurodegenerative diseases, or heart and vascular diseases. The invention is in the field of dietary (...  
WO/2012/037466A8
Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and...  
WO/2012/029529A1
The present invention addresses the problem of providing an eggshell membrane solubilization method that is capable of solving the problems associated with carrying out treatment using acids and alkalis, or problems associated with the p...  
WO/2012/027794A3
The present invention relates generally to a method of treating conditions characterised by aberrant amyloid precursor protein ferroxidase activity and agents useful for same. More particularly, the present invention relates to a method ...  
WO/2012/025877A1
The present invention relates to (S)-proline sulfonamide compounds of formula (I), wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or...  
WO/2012/027277A3
The invention provides a formulation for treating stress and lessening fatigue. The formulation can be combined with water or another suitable liquid to provide a beverage for ease of administration. The formulation can include one or mo...  
WO/2012/027277A2
The invention provides a formulation for treating stress and lessening fatigue. The formulation can be combined with water or another suitable liquid to provide a beverage for ease of administration. The formulation can include one or mo...  
WO/2012/026346A1
The purpose is to find a novel and useful component in a culture supernatant of a lactic acid bacterium and to provide an effective use of the ingredient. The component is used to provide a cytoprotective agent which comprises a low-mole...  
WO/2012/017367A1
The present invention regards a composition comprising Glutathione Reductase (GSSG-r) and Oxidized Glutathione (GSSG) or pharmaceutically acceptable salts thereof for pharmaceutical use as antiviral and antibacterial agents and for the p...  
WO/2012/016384A1
A composition of plant material for improving symptoms of fatigue, improving sleep quality and preparation method, use and products thereof, said composition is prepared by using Rhodiola L.20-80%, Gynostemma BL.10-60% and Lycium L.10-60%.  
WO/2012/017748A1
To provide an adsorbent for oral administration which has a high ability to adsorb indoxyl sulfate, indoleacetic acid, and indole, a method capable of easily and advantageously producing the same, and a drug using the same. The adsorbent...  
WO/2012/017451A1
A bio-stabilized resveratrol formulation for the treatment of diseases and conditions selected from the group consisting of cancer, Alzheimer's disease, obesity, metabolic diseases, cardiac diseases, viral diseases, inflammation, impaire...  
WO/2012/017551A1
[Problem] To provide a therapeutic agent for disease capable of delivering iron or manganese porphyrin complex possessing the ability to remove active oxygen, principally to abnormal tissue in a living body to effectively remove the acti...  
WO/2012/013020A1
An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single u...  
WO/2012/013020A8
An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single u...  
WO/2012/011071A1
The present invention concerns a composition comprising a low dosage of at least one venom derived from a venomous snake, characterised in that said composition is diluted in an aqueous medium according to the Sequential Kinetic Activati...  
WO/2012/008457A1
The present invention provides a composition for external application, which contains a vitamin A, a heparin analogue and an antioxidant. The present invention also provides a composition for external application for improving rough skin...  
WO/2012/004875A1
[Problem] To provide an antioxidant which has an effective antioxidant effect without showing any side effects. [Solution] A novel substance represented by formula (1).  
WO/2011/160252A1
Organic acid salts of Penehyclidine optical isomer, specifically compounds of formula (I), crystals, solvates or pro-drugs thereof are disclosed, in which n and HX are as defined in the specification. The methods for preparing compounds ...  
WO/2011/162639A1
The invention relates to the field of synthesizing high molecular weight chemical compounds that exhibit biological activity for the production of highly effective pharmacological preparations and vaccines and, more specifically, to hete...  
WO/2011/158089A1
Compositions comprising N-containing polymers to suppress the metal induced allergic reactions in sensitized subjects. More particularly, the inventive composition are intend to prevent allergies to immunogenic metals in a subject with a...  
WO/2011/154630A1
The invention relates to a gaseous composition containing an effective amount of gaseous krypton for use via inhalation for preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it cont...  
WO/2011/156729A3
The present invention is directed to methods of reducing mortality in a subject exposed to a lethal dose of radiation comprising administering to the subject an effective amount of a thrombin peptide derivative described herein. Also inc...  
WO/2011/152751A1
The invention relates to the pharmaceutical industry, and specifically to a composition based on 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone (ubinone, ubiquinone, coenzyme Q10) in liquid form, which can be used for the prophylax...  
WO/2011/152330A1
Disclosed is an antioxidant which exhibits high antioxidation activity and can be used in food, drink or pharmaceutical products. An antioxidant that exhibits high antioxidation activity can be provided by obtaining a soybean protein hyd...  
WO/2011/149011A1
Disclosed are: the compound represented by formula (1) or a salt thereof; and a manufacturing intermediate therefor. Said compound exhibits excellent antioxidant activity in a microsomal lipid peroxidation measurement system using rat-li...  
WO/2011/143843A1
An atomizing formulation comprising plant extract and its preparation method are disclosed. The atomizing formulation consists of tea polyphenol, vitamin E, essence and diluent. Its preparation method comprises the steps of: crushing gre...  
WO/2011/139897A3
α-tocopherol quinone is chemically reduced by combination with a reducing agent, such as tin (II) ion in the form of stannous chloride (SnCl2-2H20), or by chromium (III) ion, such as chromium (III) in the form of chromium chloride (CrCl...  
WO/2011/139897A2
α-tocopherol quinone is chemically reduced by combination with a reducing agent, such as tin (II) ion in the form of stannous chloride (SnCl2-2H20), or by chromium (III) ion, such as chromium (III) in the form of chromium chloride (CrCl...  
WO/2011/134019A1
The present invention relates to compounds and compositions useful in modulating the renin-angiotensin system (RAS) in cells, and in particular to compounds which, inter alia, act as angiotensin II antagonists by binding to angiotensin I...  
WO/2011/136573A2
The present invention relates to a yeast hydrolysate, which inhibits the deposition of fat around internal organs so as to treat or prevent obesity, and which has antioxidant activity. In addition, the present invention relates to a meth...  
WO/2011/136573A3
The present invention relates to a yeast hydrolysate, which inhibits the deposition of fat around internal organs so as to treat or prevent obesity, and which has antioxidant activity. In addition, the present invention relates to a meth...  
WO/2011/123890A1
The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection). Preferred compounds of the invention are those of Formula (II), as follow...  
WO/2011/124234A1
Synthesis of nano-hydroxyapatite by an organic-inorganic complexion route. Such material was injected intravenously into rats after the exposure of these rats to LD50 of toxic heavy metal. The prepared nano-hydroxyapatite success in repa...  
WO/2011/117690A1
The present invention relates to the use of hydroxyl-2, 3- diarylxanthones (DAX) as therapeutic agent of pathologies due to reactive oxygen species. Certain polyhydroxy-2, 3-diaryl-9H-xanthen-9-ones present antioxidant properties much hi...  
WO/2011/116216A2
Topical skin care compositions containing a combination of ascorbic acid or a derivative thereof, brown algae extract, and a blend of botanical extracts comprising cucumber extract, watercress extract, birch leaf extract, red clover extr...  
WO/2011/113300A1
Compounds of formula (1) or a derivative thereof, acipimox, are used in combination with several chemotherapeutic agents for inhibition of toxicity or side effects caused by chemotherapeutic agents, while do not attenuate chemotherapeuti...  
WO/2011/110661A1
An antioxidant composition is described for reducing oxidative stress in subjects undergoing hormonal contraceptive drug treatment. In particular, said composition has proved to be particularly suitable because, as well as being surprisi...  
WO/2011/111577A1
Provided is an adsorption carbon which can effectively adsorb toxins, such as advanced glycation end-products (AGEs), within a living body. Also provided is an adsorbent which contains said adsorption carbon as the active ingredient. The...  
WO/2011/107877A3
A compound, composition and method of making and using a compound of formula (1) are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The com...  
WO/2011/107881A3
A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceu...  
WO/2011/107870A3
A compound, composition, method of synthesizing and using the compound of formula (I) are disclosed. The compound of formula (I) also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharm...  
WO/2011/107259A1
The subject invention relates to a chocolate or compound chocolate product comprising added functional ingredients including vitamin C, vitamin E, zinc, copper and, optionally, a xanthophyll. The invention further concerns the production...  
WO/2011/107867A3
A compound, composition and method of making and using a compound of formula (1) are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The com...  
WO/2011/105424A1
The purpose of the present invention is to find a ligand for a DCIR and to search for a stimulant and an antagonist for the DCIR. Specifically disclosed are: a dendritic cell immunoreceptor stimulant which contains keratan sulfate II (KS...  
WO/2011/102310A1
Disclosed is a blood uric acid level lowering agent, which is derived from a natural material and can be ingested continuously for a long period. The blood uric acid level lowering agent comprises an enzymatic decomposition product of a ...  
WO/2011/103536A1
The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such...  
WO/2011/099526A1
Disclosed is a biocompatible solution which can deliver a sufficient quantity of hydrogen molecules into cells. Specifically disclosed is a hydrogen-containing hypotonic biocompatible solution which contains hydrogen molecules, contains ...  

Matches 301 - 350 out of 9,945